Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study
- PMID: 24005903
- DOI: 10.1001/jamadermatol.2013.5768
Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study
Abstract
Importance: Topical corticosteroids are indicated for pregnant women with skin conditions, but their safety in pregnancy is not fully understood.
Objective: To investigate whether maternal exposure to topical corticosteroids results in adverse pregnancy outcomes.
Design: Retrospective cohort study.
Setting: United Kingdom National Health Service.
Participants: A total of 2658 pregnant women exposed to topical corticosteroid and 7246 unexposed pregnant women.
Exposure: Topical corticosteroids dispensed during pregnancy.
Main outcomes and measures: Orofacial cleft, low birth weight, preterm delivery, fetal death, low Apgar score, and mode of delivery.
Results: No associations of maternal topical corticosteroid exposure with orofacial cleft, low birth weight, preterm delivery, fetal death, low Apgar score, and mode of delivery were found in the primary analysis (adjusted risk ratio [RR], 1.85 [95% CI, 0.22-15.20] [P = .57]; 0.97 [95% CI, 0.78-1.19] [P = .75]; 1.20 [95% CI, 0.73-1.96] [P = .48]; 1.07 [95% CI, 0.56-2.05] [P = .84]; 0.84 [95% CI, 0.54-1.31] [P = .45]; and P = .76, respectively). Stratified analyses based on potency did not reveal any significant associations in most of these categories either, but an exploratory analysis showed a significantly increased risk of low birth weight when the dispensed amount of potent or very potent topical corticosteroids exceeded 300 g during the entire pregnancy (adjusted RR, 7.74 [95% CI, 1.49-40.11]; P = .02).
Conclusions and relevance: This study reassuringly showed no associations of maternal topical corticosteroid exposure with orofacial cleft, preterm delivery, fetal death, low Apgar score, and mode of delivery. With this study and all available evidence taken together, the risk of low birth weight seems to correlate with the quantity of topical corticosteroid exposure.
Similar articles
-
Safety of topical corticosteroids in pregnancy.Cochrane Database Syst Rev. 2015 Oct 26;2015(10):CD007346. doi: 10.1002/14651858.CD007346.pub3. Cochrane Database Syst Rev. 2015. PMID: 26497573 Free PMC article. Review.
-
Safety of topical corticosteroids in pregnancy.Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007346. doi: 10.1002/14651858.CD007346.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2015 Oct 26;(10):CD007346. doi: 10.1002/14651858.CD007346.pub3. PMID: 19588425 Updated. Review.
-
Safety of topical corticosteroids in pregnancy: a population-based cohort study.J Invest Dermatol. 2011 Apr;131(4):884-91. doi: 10.1038/jid.2010.392. Epub 2010 Dec 30. J Invest Dermatol. 2011. PMID: 21191410
-
Evidence-based (S3) guideline on topical corticosteroids in pregnancy.Br J Dermatol. 2011 Nov;165(5):943-52. doi: 10.1111/j.1365-2133.2011.10513.x. Epub 2011 Sep 29. Br J Dermatol. 2011. PMID: 21729030 Review.
-
Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy.Acta Obstet Gynecol Scand. 2002 Mar;81(3):234-9. doi: 10.1034/j.1600-0412.2002.810308.x. Acta Obstet Gynecol Scand. 2002. PMID: 11966480
Cited by
-
Oversight and Management of Women with Psoriasis in Childbearing Age.Medicina (Kaunas). 2022 Jun 9;58(6):780. doi: 10.3390/medicina58060780. Medicina (Kaunas). 2022. PMID: 35744043 Free PMC article. Review.
-
Pruritus in Pregnancy.Am J Clin Dermatol. 2022 Mar;23(2):231-246. doi: 10.1007/s40257-021-00668-7. Epub 2022 Feb 21. Am J Clin Dermatol. 2022. PMID: 35191007 Free PMC article. Review.
-
State-of-the-Art Review of Pregnancy-Related Psoriasis.Medicina (Kaunas). 2021 Aug 5;57(8):804. doi: 10.3390/medicina57080804. Medicina (Kaunas). 2021. PMID: 34441010 Free PMC article. Review.
-
Evaluation of Topical Corticosteroid Use in Pregnancy and Risk of Newborns Being Small for Gestational Age and Having Low Birth Weight.JAMA Dermatol. 2021 Jul 1;157(7):788-795. doi: 10.1001/jamadermatol.2021.1090. JAMA Dermatol. 2021. PMID: 33950165 Free PMC article.
-
Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature.Dermatol Ther (Heidelb). 2020 Dec;10(6):1215-1228. doi: 10.1007/s13555-020-00457-w. Epub 2020 Nov 2. Dermatol Ther (Heidelb). 2020. PMID: 33140290 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical